

JAN 08 2003

file copy

PTO FORM 4/92

Page 1 of 1

FORM PTO - 1449

**LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION
DISCLOSURE STATEMENT**

ATTY DOCKET: 10738-44
APPLICANTS: Kersten M. Small et al
FILING DATE: August 10, 2000
**FOR: ALPHA-2A-ADRENERGIC
RECEPTOR POLYMORPHISMS**

SERIAL NO.
09/636,259

GROUP: 1634

UNITED STATES LETTERS PATENT

Exr. Init.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS
aa	5 5 9 5 8 8 0	Jan. 21, 1997	Weinshank et al		

RECEIVED

JAN 10 2003

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS
ba WO 01 2 9 0 8 2	April 26, 2001	PCT		

TECH CENTER 1600/2900

OTHER ART (INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)

ca	HEINONEN P. et al: "Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects." <i>The Journal of Clinical Endocrinology and Metabolism</i> , United States, July 1999, Vol. 84, No. 7, pages 2429-2433.
cb	BALDWIN C.T., et al: "Identification of a polymorphic glutamic acid stretch in the alpha2B-adrenergic receptor and lack of linkage with essential hypertension." <i>American Journal of Hypertension: Journal of the American Society of Hypertension</i> , United States, Sep. 1999, Vol. 12, No. 9, Pt. 1, pages 853-857.
cc	JEWELL-MOTZ, E.A. et al: "An acidic motif within the third intracellular loop of the alpha2C2 adrenergic receptor is required for agonist-promoted phosphorylation and desensitization." <i>Biochemistry</i> , United States 19 Sep. 1995, Vol. 34, No. 37, 19 September 1995, pages 11946-11953.
cd	COMINGS, D.E., et al: "Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects." <i>Clinical Genetics</i> , Denmark, March 1999, Vol. 55, No. 3, pages 160-172.
ce	MAKARITSIS K.P., et al: "Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension." <i>Hypertension</i> . United States, Jan. 1999, Vol. 33, No. 1, January 1999, pages 14-17.
cf	MICHEL M.C., et al: "Functional correlates of alpha(2A)-adrenoceptor gene polymorphism in the HANE study." <i>Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association-European Renal Association</i> . England, Nov. 1999, Vol. 14, No. 11, pages 2657-2663.
cg	FREEMAN K., et al: "Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans." <i>American Journal of Hypertension: Journal of the American Society of Hypertension</i> . United States, Sep. 1995, Vol. 8, No. 9, pages 863-869.
ch	SMALL K.M., et al: "Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization." <i>The Journal of Biological Chemistry</i> . United States, 16 Feb 2001, Vol. 276, No. 7, pages 4917-4922.
ci	SNAPIR A., et al: "An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events." <i>Journal of the American College of Cardiology</i> . United States, May 2001, Vol. 37, No. 6, pages 1516-1522.

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.

857464v1
10738-44

Diana B

3/5/03

file
copy
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY DOCKET NO.
13092SERIAL NO.
09/636,259FILING
August 10, 2000GROUP
1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DP	5,648,482	07/15/97	Meyer			
	5,846,710	12/08/98	Bajaj			
	5,856,092	01/05/99	Dale et al.			
	5,888,819	03/30/99	Goelet et al.			
	5,981,174	11/09/99	Wolf et al.			
	6,004,744	12/21/99	Goelet et al.			
	6,013,431	01/11/00	Soderlund et al.			
DP	6,156,503	12/05/00	Drazen et al.			

RECEIVED

APR 10 2001

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DP		Limbird, L.E. (1988) FASEB J 2, 2686-2695.
DP		Luttrell, L.M., van Biesen, T., Hawes, B.E., Della Rocca, G.J., Luttrell, D.K., and Lefkowitz, R.J. (1998) in Catecholamines: Bridging Basic Science with Clinical Medicine (Goldstein, D.S., Eisenhofer, G., and McCarty, R., eds) pp. 466-470, Academic Press.


EXAMINER

Diana B.

DATE CONSIDERED

3/5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Docket Number (Optional) 13092	Application Number 09/636,259
Applicant(s) Small et al.	
Filing Date August 10, 2000	Group Art Unit 1645


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)



	Ruffolo, R.R., Jr., Nichols, A.J., Stadel, J.M., and Hieble, J.P. (1993) Annu Rev Pharmacol Toxicol 32, 243-279.	RECEIVED
	Hein, L., Altman, J.D., and Kobilka, B.K. (1999) Nature 402, 181-184.	APR 10 2001
	Altman, J.D., Trendelenburg, A.U., MacMillan, L., Bernstein, D., Limbird, L., Starke, K., Kobilka, B.K., and Hein, L. (1999) Mol.Pharmacol. 56, 154-161.	TECH CENTER 1600/2900
	Lakhani, P.P., MacMillan, L.B., Guo, T.Z., McCool, B.A., Lovinger, D.M., Maze, M., and Limbird, L.E. (1997) Proc Natl Acad Sci USA 94, 9950-9955.	
	Holmes, B., Brogden, R.N., Heel, R.C., Speight, T.M., and Avery, G.S. (1983) Drugs 26, 212-229.	
	Dao, T.T., Kailasam, M.T., Parmer, R.J., Le, H.V., Le Verge, R., Kennedy, B.P., Ziegler, G., Insel, P.A., Wright, F.A., and O'Connor, D.T. (1998) J Hypertens 16, 779-792.	
	Goldstein, D.S., Grossman, E., Listwak, S., and Folio, C.J. (1991) Hypertension 18, III40-III48.	
	Lockette, W., Ghosh, S., Farrow, S., MacKenzie, S., Baker, S., Miles, P., Schork, A., and Cadaret, L. (1995) Am J Hypertens 8, 390-394.	
	Svetkey, L.P., Timmons, P.Z., Emovon, O., Anderson, N.B., Preis, L., and Chen, Y.-T. (1996) Hypertension 27, 1210-1215.	
	Liggett, S.B. (1998) Clin and Exp.Allergy 28, 77-79.	
	Guyer, C.A., Horstman, D.A., Wilson, A.L., Clark, J.D., Cragoe, E.J.Jr., and Limbird, L.E. (1990) J Biol Chem 265, 17307-17317.	
	 Onions, K.L., Hunt, S.C., Rutkowski, M.P., Klanke, C.A., Su, Y.R., Reif, M., and Menon, A.G. (1998) Hypertension 31, 1230-1234.	


EXAMINER

DATE CONSIDERED
3/5/03

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Docket Number (Optional) 13092	Application Number 09/636,259
	Applicant(s) Small et al.	
	Filing Date August 10, 2000	Group Art Unit 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Eason, M.G. and Liggett, S.B. (1992) J.Biol.Chem. 267, 25473-25479.	<div>RECEIVED</div> <div>APR 10 2001</div> <div>TECH CENTER 1600/2900</div>
	Jewell-Motz, E.A. and Liggett, S.B. (1996) J.Biol.Chem. 271, 18082-18087.	
	de chasseval, R. and de Villartay, J.-P. (1991) Nucleic Acids Research 20, 245-250.	
	Eason, M.G., Moreira, S.P., and Liggett, S.B. (1995) J.Biol.Chem. 270, 4681-4688.	
	Jewell-Motz, E.A., Donnelly, E.T., Eason, M.G., and Liggett, S.B. (1998) Biochem 37, 15720-15725.	
	Schwinn, D.A., Page, S.O., Middleton, J.P., Lorenz, W., Liggett, S.B., Yamamoto, K., Caron, M.G., Lefkowitz, R.J., and Cotecchia, S. (1991) Mol.Pharmacol. 40, 619-626.	
	Martin, T.F.J. (1983) J Biol Chem 258, 14816-14822.	
	Eason, M.G., Jacinto, M.T., Theiss, C.T., and Liggett, S.B. (1994) Proc.Natl.Acad.Sci., USA 91, 11178-11182.	
	Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J., and Klenk, D.C. (1985) Anal.Biochem. 150, 76-85.	
	Eason, M.G. and Liggett, S.B. (1996) J.Biol.Chem. 271, 12826-12832.	
	Exton, J.H. (1996) Annu Rev Pharmacol Toxicol 36, 481-509.	
	MacMillan, L.B., Lakhani, P., Lovinger, D., and Limbird, L.E. (1998) Recent Prog Horm Res 53, 25-42.	

EXAMINER 	DATE CONSIDERED 3/5/03
--	-------------------------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Docket Number (Optional)	Application Number
	13092	09/636.259
	Applicant(s) Small et al.	
Filing Date	Group Art Unit	
August 10, 2000	1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Makaritsis, K.P., Johns, C., Gavras, I., Altman, J.D., Handy, D.E., Bresnahan, M.R., and Gavras, H. (1999) Hypertension 34, 403-407.
	Spiegel, A.M. (1996) Annu Rev Physiol 58, 143-170.
	Kotanko, P., Binder, A., Tasker, J., DeFreitas, P., Kamdar, S., Clark, A.J., Skrabal, F., and Caulfield, M. (1997) Hypertension 30, 773-776.
	Liggett, S.B., Wagoner, L.E., Craft, L.L., Hornung, R.W., Hoit, B.D., McIntosh, T.C., and Walsh, R.A. (1998) J Clin Invest 102, 1534-1539.
	Tan, S., Hall, I.P., Dewar, J., Dow, E., and Lipworth, B. (1997) Lancet 350, 995-999.
	Green, S.A., Cole, G., Jacinto, M., Innis, M., and Liggett, S.B. (1993) J Biol Chem 268, 23116-23121.
	Shenker, A., Laue, L., Kosugi, S., Merendino, J.J., Minegishi, T., and Cutler, G.B. (1993) Nature Lond 365, 652-654.
	"Introduction to α -adrenoceptors,"
	http://www.adrenoceptor.com/alphaintro.htm (visited April 2, 2001) (pp. N/A) (author N/A)
	Robinson, E. and Hudson A. "Adrenoceptor Pharmacology,"
	http://www.tocris.com/adrenoceptor.htm (visited March 12, 2001) (pp. N/A)
	November 1998

EXAMINER	DATE CONSIDERED
	3/5/03

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.